DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Reactogenicity
Reactogenicity
Version Gdsv27/Ipiv21
Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP® DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults
Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: a Vaccine Recipient Survey
Cervarix
Reactogenicity, Contraindications, and Precautions: Mrna COVID-19 Vaccines
ACIP COVID-19 Vaccine Bnt162b2-May 12, 2021
Submitting Study Datasets for Vaccines to the Office of Vaccines Research and Review
Safety and Immunogenicity of a Plant-Produced
Gardasil, INN-Human Papillomavirus Vaccine [Types 6, 11, 16
Immunogenicity and Safety of an AS03A-Adjuvanted H5N1 Influenza Vaccine in a Taiwanese Population
Pandemic Influenza А/H5N1 Vaccine Kazfluvac
Cervarix HPV Vaccination Series [1]
COVID-19 Vaccine Safety Update
Virus-Like-Vaccines Against HIV
Advisory Committee on Immunization Practices (Acip)
HIV Pathogenesis and Vaccine Development Volume 13 Issue 1 March/April 2005
CDC/IDSA COVID-19 Clinician Call January 23, 2021
Points to Concider on the Reduction, Elimination Or Substitution of Thiomersal in Vaccines
Top View
Longer Interval Versus Shorter Interval Between Two HPV Vaccine Doses
Study Protocol
HIV Vaccine Clinical Trials: an Overview
FDA Briefing Document: Moderna COVID-19 Vaccine
STUDY PROTOCOL V122 01 Version 1.0
Influenza Vaccine Rates Information Sheet
HPV Vaccine Frequently Asked Questions for Health Professionals
Reactogenicity Following Receipt of Mrna-Based COVID-19 Vaccines
MODULE 3 Adverse Events Following Immunization MODULE 3: Adverse Events Following Immunization
Serious Adverse Events Associated with HPV Vaccination
Day-To-Day Reactogenicity and the Healthy Vaccinee Effect of Measles-Mumps-Rubella Vaccination
Protocol HVTN 108 Are Described Below
Cervarix® Human Papillomavirus Vaccine Types 16 and 18 (Recombinant, AS04 Adjuvanted) Active Immunizing Agent Glaxosmithkline Date of Revision: November 25, 2014
An Observational Study of the Reactogenicity and Immunogenicity
Influenza a (H5N1) Virus Monovalent Vaccine, Adjuvanted
Menb JAMA.Pdf
Safety, Reactogenicity, and Immunogenicity of Homologous and Heterologous Prime-Boost Immunisation with Chadox1-Ncov19 and Bnt162b2: a Prospective Cohort Study
Immunogenicity of Hbv Vaccine During Stated Shelf-Life
ENSEMBLE Study Protocol
Combined Administration of Serogroup B Meningococcal Vaccine and Conjugated Serogroup C Meningococcal Vaccine Is Safe and Immunogenic in College Students
Immunogenicity and Protective Efficacy of a Non-Living
Annex 1 Who Guidelines on Clinical Evaluation of Vaccines
Recent Developments in the Understanding and Use of Anthrax Vaccine Adsorbed: Achieving More with Less
COVID-19 Vaccine Safety Update—January 2021
Cervarix, INN-Human Papillomavirus Vaccine
Short-Term Reactogenicity and Gender Effect of Anthrax Vaccine: Analysis of a 1967–1972 Study and Review of the 1955–2005 Medical Literaturez,§
Virus Vaccine Administered with Or Without AS03 Adjuvant
Reactogenicity and Immunogenicity at Preschool Age of a Booster Dose of Two Three-Component Diphtheria-Tetanus-Acellular Pertuss
The Case of Deadly Anthrax Infection, Vaccine Development and Evolution and Edema Factor (EF)
Influenza a (H5N1) Virus Monovalent Vaccine, Adjuvanted
Virus-Like Particle-Based L2 Vaccines Against Hpvs: Where Are We Today?
Mrna-1273 Vaccine (Moderna) Against COVID-19 Background Document
Information Sheet Observed Rate of Vaccine Reactions
Robust Spike Antibody Responses and Increased Reactogenicity in Seropositive Individuals After a Single Dose of SARS-Cov-2 Mrna
Adverse Reactions to Vaccines Practice Parameter 2012 Update
Immunogenicity and Reactogenicity of the Adult Tetanus–Diphtheria Vaccine. How Many Doses Are Necessary?
Meeting Report Thiomersal in Vaccines: a Regulatory Perspective